Arrowhead Pharmaceuticals Inc

17 de set. de 2026, 22:56 UTC

Arrowhead Pharmaceuticals Inc is trading roughly flat in after-market hours, maintaining little change since Thursday's close amid a notable decline over the past month.

16 de set. de 2026, 22:31 UTC

Arrowhead Pharmaceuticals Inc is rising in after-market trading, rebounding sharply amid retail commentary on its resilience despite challenges in the biotechnology sector.

15 de set. de 2026, 23:01 UTC

Arrowhead Pharmaceuticals is gaining in after-market hours following positive interim data from its ARO-DIMER-PA trial, amid a broader market uptrend.

14 de set. de 2026, 19:16 UTC

Arrowhead Pharmaceuticals Inc shares are lower amid broader market pressures, driven by renewed inflation concerns and supply chain disruptions.

11 de set. de 2026, 23:26 UTC

Arrowhead Pharmaceuticals shares rose in after-market trading, amid steady U.S. inflation data and speculation about potential Federal Reserve interest rate hikes.

10 de set. de 2026, 19:56 UTC

Arrowhead Pharmaceuticals shares are higher during Thursday's session, despite fluctuations and remaining below the 20-day moving average amid broader market trends.

9 de set. de 2026, 19:36 UTC

Arrowhead Pharmaceuticals is lower today despite Citi initiating coverage with a "Buy" rating and a price target of $108. The stock has declined for four sessions.

8 de set. de 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading lower today, following Citi's initiation of coverage with a Buy rating and a $108 price target.

4 de set. de 2026, 23:10 UTC

Arrowhead Pharmaceuticals Inc shares are lower in after-market hours following Friday's close. Broader market caution amid mixed economic signals may be influencing this movement.

3 de set. de 2026, 19:46 UTC

Arrowhead Pharmaceuticals shares are higher as the company announces participation in several upcoming investor conferences, enhancing visibility among investors and analysts.

2 de set. de 2026, 23:01 UTC

Arrowhead Pharmaceuticals Inc is trading lower in after-market hours, reflecting a notable decline since Wednesday's close amid broader market tensions and rising oil prices.

1 de set. de 2026, 19:46 UTC

HC Wainwright reiterated its Buy rating on Arrowhead Pharmaceuticals, maintaining a $120 price target as shares advance during the session.

31 de ago. de 2026, 20:01 UTC

Arrowhead Pharmaceuticals shares are lower despite promising Phase 3 results for plozasiran, which showed significant triglyceride reductions in patients.

28 de ago. de 2026, 21:01 UTC

Arrowhead Pharmaceuticals Inc. shares are higher in after-market trading, continuing a modest rise since Friday's close, despite remaining below the 20-day moving average.

26 de ago. de 2026, 19:56 UTC

Arrowhead Pharmaceuticals shares are lower today, trading within a narrow range without any specific news or developments identified.

25 de ago. de 2026, 23:31 UTC

Arrowhead Pharmaceuticals shares moved higher in after-market trading, remaining near the upper end of their one-month range. No specific news was identified.

21 de ago. de 2026, 19:46 UTC

Arrowhead Pharmaceuticals shares are lower as Director Michael Perry sold 11,600 shares, reducing his ownership. Rising Treasury yields may also affect sentiment in biotechnology.

20 de ago. de 2026, 21:26 UTC

Arrowhead Pharmaceuticals Inc shares are lower during after-market hours. Broader market pressure from rising U.S. Treasury yields may be influencing sentiment.

19 de ago. de 2026, 19:26 UTC

Arrowhead Pharmaceuticals shares are higher Wednesday, supported by gains in the biotech sector, as the stock remains above its 20-day moving average.

18 de ago. de 2026, 23:01 UTC

Arrowhead Pharmaceuticals shares are lower in after-market hours, continuing a decline since Tuesday's close amid broader market concerns over rising U.S. Treasury yields.

14 de ago. de 2026, 19:26 UTC

Arrowhead Pharmaceuticals Inc shares are higher during Friday's session, trading above their 20-day moving average and near the top of their one-month range.

13 de ago. de 2026, 20:06 UTC

Arrowhead Pharmaceuticals Inc is declining today amid broader sector pressures, reflecting challenges in the biotech sector linked to the performance of LABU.

12 de ago. de 2026, 21:01 UTC

Arrowhead Pharmaceuticals shares are higher in after-market hours, buoyed by positive market sentiment following comments on interest rates from Economic Advisor Phelan.

11 de ago. de 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher today, remaining above its 20-day moving average amid geopolitical tensions and anticipation of U.S. inflation reports.

6 de ago. de 2026, 19:16 UTC

Arrowhead Pharmaceuticals Inc shares are lower during Thursday's session, despite earlier rebounding from a session high. No specific news was identified to explain the decline.

5 de ago. de 2026, 21:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher in after-market hours, reflecting strong performance and positioning above its 20-day moving average.

4 de ago. de 2026, 23:02 UTC

Arrowhead Pharmaceuticals shares fell in after-market trading following a net loss of $194.280 million and an EPS of -$1.36 in its fiscal Q3 results.

3 de ago. de 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher in Monday's session. Broader market positivity follows President Trump's military announcement, impacting crude oil prices.

31 de jul. de 2026, 19:16 UTC

Arrowhead Pharmaceuticals shares are lower, reflecting broader pressures in the biotechnology sector amid rising inflation concerns linked to increased crude oil prices.

30 de jul. de 2026, 23:06 UTC

Arrowhead Pharmaceuticals Inc shares declined in after-market trading, with no specific news identified to explain the movement amid broader market volatility.